Study of adverse outcomes in women using testosterone therapyVAN STAA, T. P; SPRAFKA, J. M.Maturitas (Amsterdam). 2009, Vol 62, Num 1, pp 76-80, issn 0378-5122, 5 p.Article

A study of the effects of exposure misclassification due to the time-window design in pharmacoepidemiologic studiesVAN STAA, T.-P; ABENHAIM, L; LEUFKENS, H et al.Journal of clinical epidemiology. 1994, Vol 47, Num 2, pp 183-189, issn 0895-4356Article

The potential effects on fracture outcomes of improvements in persistence and compliance with bisphosphonatesRIETBROCK, S; OLSON, M; VAN STAA, T. P et al.QJM (Oxford. 1994. Print). 2009, Vol 102, Num 1, pp 35-42, issn 1460-2725, 8 p.Article

Use of cyclical etidronate and prevention of non-vertebral fracturesVAN STAA, T. P; ABENHAIM, L; COOPER, C et al.British journal of rheumatology. 1998, Vol 37, Num 1, pp 87-94, issn 0263-7103Article

Utility of medical and drug history in fracture risk prediction among men and womenVAN STAA, T. P; LEUFKENS, H. G. M; COOPER, C et al.Bone (New York, NY). 2002, Vol 31, Num 4, pp 508-514, issn 8756-3282, 7 p.Article

Changes in the Characteristics of Patients Prescribed Selective Cyclooxygenase 2 Inhibitors After the 2004 Withdrawal of RofecoxibSETAKIS, E; LEUFKENS, H. G. M; VAN STAA, T. P et al.Arthritis care and research. 2008, Vol 59, Num 8, pp 1105-1111, issn 0893-7524, 7 p.Article

Use of nonsteroidal anti-inflammatory drugs and risk of fracturesVAN STAA, T. P; LEUFKENS, H. G. M; COOPER, C et al.Bone (New York, NY). 2000, Vol 27, Num 4, pp 563-568, issn 8756-3282Article

Use of inhaled corticosteroids and risk of fracturesVAN STAA, T. P; LEUFKENS, H. G. M; COOPER, C et al.Journal of bone and mineral research (Print). 2001, Vol 16, Num 3, pp 581-588, issn 0884-0431Article

Children and the risk of fractures caused by oral corticosteroidsVAN STAA, T. P; COOPER, C; LEUFKENS, H. G. M et al.Journal of bone and mineral research (Print). 2003, Vol 18, Num 5, pp 913-918, issn 0884-0431, 6 p.Article

Oral corticosteroids and fracture risk: relationship to daily and cumulative dosesVAN STAA, T. P; LEUFKENS, H. G. M; ABENHAIM, L et al.Rheumatology (Oxford. Print). 2000, Vol 39, Num 12, pp 1383-1389, issn 1462-0324Article

Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonatesDE VRIES, F; COOPER, A. L; COCKLE, S. M et al.Osteoporosis international. 2009, Vol 20, Num 12, pp 1989-1998, issn 0937-941X, 10 p.Article

Public health impact of adverse bone effects of oral corticosteroidsVAN STAA, T. P; ABENHAIM, L; COOPER, C et al.British journal of clinical pharmacology. 2001, Vol 51, Num 6, pp 601-607, issn 0306-5251Article

Epidemiology of fractures in England and WalesVAN STAA, T. P; DENNISON, E. M; LEUFKENS, H. G. M et al.Bone (New York, NY). 2001, Vol 29, Num 6, pp 517-522, issn 8756-3282Article

What is the harm-benefit ratio of Cox-2 inhibitors?VAN STAA, T. P; SMEETH, L; PERSSON, I et al.International journal of epidemiology. 2008, Vol 37, Num 2, pp 405-413, issn 0300-5771, 9 p.Article

Does the varied use of NSAIDs explain the differences in the risk of myocardial infarction?VAN STAA, T.-P; RIETBROCK, S; SETAKIS, E et al.Journal of internal medicine. 2008, Vol 264, Num 5, pp 481-492, issn 0954-6820, 12 p.Article

Calcium and vitamin D in the prevention of osteoporotic fracturesFRANCIS, R. M; ANDERSON, F. H; PATEL, S et al.QJM (Oxford. 1994. Print). 2006, Vol 99, Num 6, pp 355-363, issn 1460-2725, 9 p.Article

5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease : a large epidemiological studyVAN STAA, T. P; CARD, T; LOGAN, R. F et al.Gut. 2005, Vol 54, Num 11, pp 1573-1578, issn 0017-5749, 6 p.Article

Postmarketing surveillance of the safety of cyclic etidronateVAN STAA, T. P; LEUFKENS, H; ABENHAIM, L et al.Pharmacotherapy. 1998, Vol 18, Num 5, pp 1121-1128, issn 0277-0008Conference Paper

Glucose-lowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary care dataVAN STAA, T. P; PATEL, D; GALLAGHER, A. M et al.Diabetologia (Berlin). 2012, Vol 55, Num 3, pp 654-665, issn 0012-186X, 12 p.Article

Use of oral corticosteroids and risk of fractures. EditorialVAN STAA, T. P; LEUFKENS, H. G. M; ABENHAIM, L et al.Journal of bone and mineral research (Print). 2000, Vol 15, Num 6, pp 993-1005, issn 0884-0431Article

Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control studySOUVEREIN, P. C; BERARD, A; VAN STAA, T. P et al.Heart (London 1996). 2004, Vol 90, Num 8, pp 859-865, issn 1355-6037, 7 p.Article

Use of antiepileptic drugs and risk of fractures : Case-control study among patients with epilepsySOUVEREIN, P. C; WEBB, D. J; WEIL, J. G et al.Neurology. 2006, Vol 66, Num 9, pp 1318-1324, issn 0028-3878, 7 p.Article

Use of oral corticosteroids in the United KingdomVAN STAA, T. P; LEUFKENS, H. G. M; ABENHAIM, L et al.QJM (Oxford. 1994. Print). 2000, Vol 93, Num 2, pp 105-111, issn 1460-2725Article

Dopaminergic drugs and the risk of hip or femur fracture: a population-based case―control studyARBOUW, M. E. L; MOVIG, K. L. L; VAN STAA, T. P et al.Osteoporosis international. 2011, Vol 22, Num 7, pp 2197-2204, issn 0937-941X, 8 p.Article

Use of anti-depressants and the risk of fracture of the hip or femurVAN DEN BRAND, M. W. M; SAMSON, M. M; POUWELS, S et al.Osteoporosis international. 2009, Vol 20, Num 10, pp 1705-1713, issn 0937-941X, 9 p.Article